Tofacitinib citrate (枸橼酸托法替尼) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively.

Ponatinib (帕纳替尼) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

S3I-201 shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.

Stattic, the first nonpeptidic small molecule, has a role as an antineoplastic agent, a STAT3 inhibitor and a radiosensitizing agent.

Nifuroxazide(硝呋齐特) is a cell-permeable and orally available nitrofuran-based antidiarrheal agent.

SH-4-54 is a potent STAT inhibitor.

AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays also potent to Aurora A/B, Abl(T315I).

AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.